Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2023 03 23T082655Z 1 LYNXMPEJ2M089 RTROPTP 4 SWISS BUSINESS - Business Express

Zur Rose delays profitability break-even to 2024


By Anastasiia Kozlova and Tristan Chabba

(Reuters) – Swiss online drug retailer Zur Rose on Thursday said it will not reach break-even in adjusted core profit this year as it navigates regulatory requirements for rolling out online prescriptions in Germany.

It had said last year it expected its adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to reach a “break-even point” in 2023.

It said it now expects a loss in adjusted EBITDA of between 20 million and 40 million Swiss francs ($22-44 million) in 2023.

“All in all, a disappointing outcome,” Baader Helvea analysts said, citing the break-even delay.

Zur Rose, which operates in Germany and the Netherlands, sold its Swiss business to Migros subsidiary Medbase in February to focus on its German business.

However, delays in Germany’s e-prescription roll-out have clouded the growth outlook for online pharmacies such as Zur Rose and Frankfurt-listed peer Shop Apotheke, and exposed their stocks to volatility.

Zur Rose said it expected e-prescriptions to be introduced as the mandatory standard by Jan. 1, 2024, citing the German Federal Ministry of Health.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

The company also reported an adjusted core loss for 2022 of 69.7 million francs, beating a company-compiled consensus of 72 million.

It had a target of 70 million to 75 million francs.

The company has decided to change its name to DocMorris AG which it will use for both for the core B2C business and the Group.

The company’s shares were down 4.3% at 0824 GMT. In 2022 the stock lost 70% of its value due to delays in the introduction of e-prescriptions in Germany.

($1 = 0.9159 Swiss francs)

 

(Reporting by Anastasiia Kozlova Tristan Chabba in Gdansk; editing by Nivedita Bhattacharjee and Jason Neely)

 

Recent Post: